

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
10 October 2002 (10.10.2002)

PCT

(10) International Publication Number
WO 02/078648 A2

(51) International Patent Classification⁷: **A61K 7/00** (74) Agent: BECKER, Konrad; Novartis AG, Corporate Intellectual Property, Patent & Trademark Department, CH-4002 Basel (CH).

(21) International Application Number: PCT/EP02/03547 (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, LZ, LC, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VN, YU, ZA, ZW.

(22) International Filing Date: 28 March 2002 (28.03.2002) (84) Designated States (*regional*): Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 0108082.9 30 March 2001 (30.03.2001) GB

(71) Applicant (*for all designated States except US*): NOVARTIS CONSUMER HEALTH S.A. [CH/CH]; Route de L'Etraz, CH-1260 Nyon (CH).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): LARNIER, Catherine [FR/CH]; 56 Grand Rue, CH-1297 Founex (CH). STEIGER, Michel [CH/CH]; Av. de la Perrausaz 90, CH-1814 La Tour-de-Peilz (CH).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

A2
WO 02/078648

(54) Title: TOPICAL COMPOSITION

(57) Abstract: The invention relates to topical pharmaceutical compositions comprising an antifungal, e.g. terbinafine, and a second drug, e.g. diclofenac or indometheacin. Said compositions exhibit beneficial antimycotic properties, especially against dermatophytes.

Topical Composition

The invention relates to topical pharmaceutical compositions with antimycotic activity, more specifically anti-dermatophyte activity.

Dermatophytes are fungi that can cause infections of the skin, hair and nails due to their ability to utilize keratin. The organisms colonize the keratin tissues and cause fungal infections, e.g. known as tinea or ringworm, in association with the infected body part. The organisms are transmitted by either direct contact with infected host (human or animal) or by direct or indirect contact with Infected exfoliated skin or hair in combs, hair brushes, clothing, furniture, theatre seats, caps, bed linens, towels, hotel rugs and locker room floors. Depending on the species the organism may be viable in the environment for up to 15 months. There is an increased susceptibility to infection when there is a pre-existing injury to the skin such as scares, burns, marching, excessive temperature and humidity.

The topical application of antifungal drugs, like terbinafine, in the treatment of fungal infections, such as mycoses, especially dermatomycoses caused by dermatophytes, e.g. athlete's foot (= tinea pedis), jock itch (= tinea cruris), ringworm, (e.g. facial) seborrheic dermatitis, or onychomycosis, is known in the art.

It has now surprisingly been found that by topical application of certain selected antifungals – in particular terbinafine – together with certain selected second drugs – in particular diclofenac and Indomethacin – the antimycotic properties are improved in an unexpected manner. Surprisingly, the combinations of the present invention are particularly beneficial in fighting dermatophytes. As already outlined above, the latter are the main cause for superficial mycoses frequently occurring in humans, such athlete's foot, jock itch or ringworm. Treatment of said superficial mycoses is generally improved by use of the specific combinations of the invention. This is quite surprising in view of the fact that the antifungals concerned are known to be rather effective in the eradication and treatment of dermatophytes even when applied alone.

There are great differences between Candida infections, e.g. with Candida albicans, and those caused by dermatophytes: Candida infections are in general much more difficult to

treat with antifungals and are often systemic. Dermatophytes, in contrast to *Candida*, never become pathogenic systemically. *Candida species*, in contrast to dermatophytes, are yeasts, are normally present in humans and usually become pathogenic only in case of overgrowth, often induced by local factors like immunodepression. The physiopathology of *Candida* and dermatophyte infections is completely different: Yeasts like *Candida* are opportunistic agents and usually need co-factors to become pathogenic, predominantly systemically. Dermatophytes, however, become immediately pathogenic when present, and on the skin exclusively.

With the combinations of the present invention, the cure of superficial mycoses caused by dermatophytes, e.g. athlete's foot, is in general achieved more quickly and a quicker relief of typical symptoms, such as itching, erythema, vesication, burning or fissures, is observed.

Therefore, the invention relates to a pharmaceutical composition adapted to topical administration comprising an antifungal selected from the group consisting of terbinafine, naftifine, butenafine, bifonazole, clotrimazole, econazole, isoconazole, ketoconazole, miconazole, oxiconazole, sertaconazole, sulconazole, tioconazole, tolnaftate, terconazole, amorolfine, ciclopirox and undecylenic acid – in particular terbinafine –, and topically acceptable salts of any of said compounds, and a second drug selected from the group consisting of diclofenac, indomethacin, flufenamic acid, niflumic acid, flurbiprofen, ibuprofen, sulfasalazine and piroxicam – in particular diclofenac or indomethacin –, and topically acceptable salts of any of said compounds, together with at least one topically acceptable carrier.

All the antifungals and drugs concerned are known and e.g. described in The Merck Index, Twelfth Edition, 1996, for example:

Terbinafine can be found under No. 9299; it is commercially available under the trademark LAMISIL. Topically acceptable salts thereof are e.g. terbinafine hydrochloride, terbinafine lactate or terbinafine ascorbate. Preferred are terbinafine and terbinafine hydrochloride, in particular terbinafine (= free base).

Diclofenac (free acid) can be found under No. 3132; it is commercially available under the trademark VOLTAREN. Topically acceptable salts thereof are e.g. diclofenac sodium, diclofenac potassium, diclofenac diethylammonium and diclofenac epolamine. Preferred is diclofenac sodium.

Indomethacin (free acid) can be found under No.4998. Topically acceptable salts thereof are e.g. indomethacin sodium (e.g. the trihydrate) or the meglumine salt of indomethacin (meglumine = N-methyl-D-glucamine). Preferred is indomethacin sodium.

Preferably, the invention relates to topical compositions, wherein the antifungal is selected from the group consisting of terbinafine, naftifine, butenafine, bifonazole, clotrimazole, isoconazole, ketoconazole, miconazole, oxiconazole, sertaconazole, sulconazole, tioconazole, tolnaftate, terconazole, amorolfine, ciclopirox, undecylenic acid, and topically acceptable salts of any of said compounds, and the second drug is selected from the group consisting of diclofenac, indomethacin, flufenamic acid, niflumic acid, flurbiprofen, sulfasalazine, piroxicam, and topically acceptable salts of any of said compounds – as well as to the use thereof.

Preferably, the antifungal is selected from the group consisting of terbinafine, naftifine, butenafine, bifonazole, clotrimazole, sertaconazole, sulconazole, tioconazole, amorolfine, ciclopirox, and topically acceptable salts of any of said compounds.

Preferably, the second drug is selected from the group consisting of diclofenac, indomethacin, flufenamic acid, niflumic acid, piroxicam, and topically acceptable salts of any of said compounds.

In another embodiment of the invention, the second drug is selected from the group consisting of ibuprofen and topically acceptable salts thereof.

Especially, the invention relates to topical compositions, wherein the antifungal is selected from the group consisting of terbinafine and topically acceptable salts thereof, and the second drug is selected from the group consisting of diclofenac, indomethacin, and topically acceptable salts of any of said compounds.

In particular, the invention relates to topical compositions, wherein the antifungal is terbinafine, or a topically acceptable salt thereof, and the second drug is diclofenac, or a topically acceptable salt thereof.

In particular preferred is the combination of terbinafine (free base) and diclofenac sodium.

A further embodiment of the invention is characterized by topical compositions, wherein the antifungal is terbinafine, or a topically acceptable salt thereof, and the second drug is indomethacin, or a topically acceptable salt thereof. Another embodiment of the invention is characterized by topical compositions, wherein the antifungal is terbinafine, or a topically acceptable salt thereof, and the second drug is ibuprofen, or a topically acceptable salt thereof.

The topically acceptable carriers used largely depend on the kind of topical composition involved (see below). They include e.g. aqueous phases, oily phases or emulsions but on the other hand also e.g. bandage materials or a transdermal patch environment.

The topical compositions of the invention have valuable pharmacological properties. Especially, they are beneficial in the treatment of infections caused by dermatophytes, such as athlete's foot, jock itch, ringworm, or onychomycosis.

It has surprisingly been found that after administration of the topical compositions of the invention patients are relieved more quickly of the symptoms accompanying superficial mycoses, such as itching, erythema, vesiculation, burning or fissures, and said superficial mycoses are in general cured more quickly.

The beneficial properties of the topical compositions of the invention can be demonstrated, for example, in the following tests.

(1) Experimental dermatophytosis model in guinea pig: It can be shown that the course of infection is stopped very effectively by the topical compositions of the invention [see S. Fujita, Congress of the International Society for Human and Animal Mycology, Abstract S23 (1997)].

(2) Controlled double-blind comparative study, involving 600 patients with established tinea pedis who are randomized to three groups of 200 each undergoing either treatment with terbinafine/diclofenac sodium (1.0%/0.5%), terbinafine/Indomethacin sodium (1%/0.5%), terbinafine alone (1.0%), diclofenac sodium alone (0.5%), indomethacin sodium alone (0.5%) or placebo (vehicle). Relief of symptoms after 1, 2 and 3 hours, 24 hours and then daily during the whole treatment period of 7 days is determined.

(3) Controlled double-blind comparative study, involving 600 patients with established tinea cruris who are randomized to three groups of 200 each undergoing either treatment with terbinafine/diclofenac sodium (1.0%/0.25%), terbinafine/Indomethacin sodium (1.0%/0.25%), terbinafine alone (1.0%) or placebo (vehicle). Relief of symptoms after 1, 2 and 3 hours, 24 hours and then daily during the whole treatment period of 7 days is determined.

(4) Controlled double-blind comparative study, involving 570 patients with established tinea pedis who are randomized to three groups of 190 each undergoing either treatment with terbinafine/diclofenac sodium (1.0%/0.1%), terbinafine/Indomethacin sodium (1.0%/0.1%), terbinafine alone (1.0%) or placebo (vehicle). Efficacy, i.e. clinical and mycological cure, is determined at 5 days, 7 days and week 6 after the beginning of treatment.

The topical compositions of the invention are likewise beneficial in the treatment of animals, especially pets and farm animals, in an analogous manner as described herein for human treatment. Therefore the invention also relates to topical veterinary compositions which are composed in the same way as the topical pharmaceutical compositions described herein.

In the topical compositions of the invention, the antifungal component – in particular terbinafine – is typically present in an amount of from 0.1 up to 10%, especially of from 0.2 up to 5%, and in particular of from 0.5 up to 2%, of the total composition on a weight basis.

In the topical compositions of the invention, the second drug, e.g. diclofenac or indomethacin, is typically present in an amount of from 0.05 up to 10%, especially of from 0.1 up to 5%, and in particular of from 0.1 up to 2%, of the total composition on a weight basis. A particular embodiment of the invention is formed by those topical compositions,

wherein the second drug is present in an amount of from 0.1 up to 0.7%, especially of from 0.1 up to 0.5% and in particular of from 0.1 up to 0.3% of the total composition.

Preferably, the topically administered pharmaceutical compositions according to the invention comprise both the antifungal and the second drug in pharmacologically effective amounts.

The daily dosage of the active ingredients may depend on various factors, such as sex, age, weight and individual condition of the patient. The topical pharmaceutical compositions, e.g. in the form of emulsion-gels, creams or ointments, may be applied once, twice or three times daily. But also more frequent daily applications are possible. Patches and bandages may be applied, for example, once or twice daily.

The invention further relates to the use of an antifungal selected from the group consisting of terbinafine, naftifine, butenafine, bifonazole, clotrimazole, econazole, isoconazole, ketoconazole, miconazole, oxiconazole, sertaconazole, sulconazole, tioconazole, tolnaftate, terconazole, amorolfine, ciclopirox, undecylenic acid, and topically acceptable salts of any of said compounds, and a second drug selected from the group consisting of diclofenac, indomethacin, flufenamic acid, niflumic acid, flurbiprofen, ibuprofen, sulfasalazine, piroxicam, and topically acceptable salts of any of said compounds, (for the manufacture of a pharmaceutical composition adapted to topical administration) for the prevention or treatment of fungal infections, in particular dermatomycoses caused by dermatophytes.

Moreover, the invention relates to a method of treating fungal infections which comprises topically administering to a mammal in need thereof a therapeutically effective amount of a mixture of an antifungal selected from the group consisting of terbinafine, naftifine, butenafine, bifonazole, clotrimazole, econazole, isoconazole, ketoconazole, miconazole, oxiconazole, sertaconazole, sulconazole, tioconazole, tolnaftate, terconazole, amorolfine, ciclopirox, undecylenic acid, and topically acceptable salts of any of said compounds, and a second drug selected from the group consisting of diclofenac, indomethacin, flufenamic acid, niflumic acid, flurbiprofen, ibuprofen, sulfasalazine, piroxicam, and topically acceptable salts of any of said compounds.

Pharmaceutical compositions suitable for topical administration are e.g. creams, lotions, ointments, microemulsions, fatty ointments, gels, foam gels, emulsion-gels, nail lacquers (varnishes), shampoos, pastes, foams, tinctures, solutions, patches, bandages and transdermal therapeutic systems; preferred are emulsion-gels, gels, foam gels, creams, lotions, solutions, shampoos and nail lacquers. The manufacture and composition of such topical pharmaceutical compositions are known in the art (see e.g. WO 98/00168 A1, pages 8-15 or US patent 5,681,849).

In a particular embodiment of the invention, topical compositions are provided wherein the two active substances of the composition are essentially separated from each other by being dissolved in different phases so that interaction between both is minimized. What essentially is prevented by doing so is the formation of salts between the antifungal, e.g. terbinafine, and the second drug drug, e.g. diclofenac or Indomethacin. Thereby typically the antifungal component, e.g. terbinafine, is dissolved or suspended in an oily phase, whereas the second drug, e.g. diclofenac or indomethacin, is dissolved or suspended in an aqueous phase.

The invention therefore further relates to a pharmaceutical composition adapted to topical administration in the form of an emulsion comprising an oily phase comprising an antifungal – as defined hereinbefore and hereinafter, in particular terbinafine –, or a topically acceptable salt thereof, and an aqueous phase comprising water, one or more solvents selected from the group consisting of C₁-C₄-alkanols, poly-hydroxy-C₂-C₅-alkanes and poly-C₂-C₅-alkylene glycols – especially a C₁-C₄-alkanol –, a water-soluble or water-miscible nonionic surfactant, wherein no anionic surfactant is present, and a second drug – as defined hereinbefore and hereinafter, especially diclofenac or Indomethacin, and in particular diclofenac –, or a topically acceptable salt thereof.

The emulsions formed are e.g. emulsion gels or fluid emulsions, and they may comprise the active substances in dissolved or suspended form.

For the oily phase, any topically acceptable oil or lipid can be used (see e.g. the "fatty phase constituents" mentioned in US patent 4,917,886, columns 4-5). Preferred is isopropyl myristate or a mixture of coco-caprylate/caprate (= a mixture of caprylic/capric acid esters of

C_{12} - C_{18} fatty alcohols, e.g. Cetiol LC) and liquid paraffin. The oily phase is e.g. present in an amount of from 2-40%, preferably 2-30%, more preferably 2-15%, in particular 4-10%, (w/w) of the total composition. The weight ratio of the terbinafine component and the oily phase is typically of from 1:3 up to 1:40, preferably of from 1:4 up to 1:20.

The weight ratio of the antifungal component – in particular terbinafine – and the second drug component – especially diclofenac or indomethacin, and in particular diclofenac – is typically of from 1:0.05 up to 1:5, and preferably of from 1:0.1 up to 1:2.

Preferably the amount of water in a said emulsion is 50 to 85% (w/w) of the total composition. Preferably the amount of lower alkanol is 5 to 35% (w/w) of the total composition. A C_1 - C_4 -alkanol preferably is a physiologically acceptable C_1 - C_4 -alkanol, e.g. isopropanol or, preferably, ethanol. Poly-hydroxy- C_2 - C_5 -alkanes have at least two hydroxy groups, preferably 2, 3 or 4, and in particular 2 or 3 hydroxy groups. Preferred as C_2 - C_5 -alkanes are C_2 - C_4 -alkanes, and in particular ethane or propane. Preferred poly-hydroxy- C_2 - C_5 -alkanes are glycerin, ethylene glycol and propylene glycol. Poly- C_2 - C_5 -alkylene glycols are e.g. polyethylene glycol or polypropylene glycol, each typically having a molecular weight of from 200 up to 12000, preferably of from 250 up to 6000 and especially of from 300 up to 1500.

Examples of water-soluble or water-miscible nonionic surfactants are: (a) Reaction products of a natural or hydrogenated castor oil and ethylene oxide, e.g. the various tensides available under the tradename Cremophor, such as Cremophor RH 40, Cremophor RH 60 or Cremophor EL. Also suitable in this category are the various tensides available under the tradename Nikkol, e.g. Nikkol HCO-60. (b) Polyoxyethylene-sorbitan-fatty acid esters or polysorbates, e.g. of the type known and commercially available under the tradenames Tween and Armoran, such as Tween 20 [polyoxyethylene(20)sorbitanmonolaurate], Tween 40, 60, 65, 80, 85, 21, 61 or 81. (c) Polyoxyethylene fatty acid esters, e.g. polyoxyethylene stearic acid esters such as those known and commercially available under the tradename Myrl, or polyoxyethylene glycerin fatty acid esters, e.g. Cetiol HE (= PEG-7 glyceryl cocoate). (d) Polyoxyethylene-polyoxypropylene co-polymers e.g. of the type known and commercially available under the tradenames Pluronic and Emkalyx. (e) Polyoxyethylene fatty alcohol ethers, e.g. polyoxyethylene stearyl ether, oleyl ether, or cetyl ether, e.g. of the type known and commercially available under the tradenames Brij, e.g. Brij 78 or 96, and

Cetomacrogol 1000. (f) Sorbitan-mono-fatty acid esters, e.g. sorbitan monolaurate (Span 20).

Conventional further excipients in said emulsions – as well as in the topical compositions of the invention in general - are, in particular, thickeners, such as carbomers (polyacrylic acid derivatives) as known and commercially available under the tradename Carbopol, e.g. Carbopol 974, 980 or 1342.

Said emulsions may be obtained e.g. by a process comprising dissolving the antifungal component – in particular terbinafine - and optionally further excipients as appropriate in the oil forming the oil phase. The latter may then be emulsified with the water phase (comprising water, one or more solvents selected from the group consisting of C₁-C₄-alkanols, poly-hydroxy-C₂-C₆-alkanes and poly-C₂-C₆-alkylene glycols - especially a C₁-C₄-alkanol -, a nonionic surfactant, the second drug component, e.g. diclofenac or indomethacin, and optionally further excipients as appropriate). Optionally, the emulsions obtained are finally incorporated into a pre-prepared gel concentrate comprising the thickener and further excipients as appropriate. In that case, the thickener (carbomer) is preferably neutralized before being mixed with the emulsion.

Further conventional excipients in said emulsions – as well as in the topical compositions of the invention in general – are e.g. complexing agents, additives to adjust the pH, antimicrobial preservatives, antioxidants, flavours or colorants.

The following examples are intended to illustrate the invention.

Example 1: A gel comprising 1% terbinafine hydrochloride and 1% diclofenac sodium is manufactured as follows.

<u>Ingredients</u>	<u>Amount (g/100g)</u>
(A) terbinafine HCl	1.00
(B) diclofenac sodium	1.00
(C) sodium pyrosulfite	0.02
(D) disodium edetate dihydrate (e.g. Komplexon III)	0.02
(E) propylene glycol	0.70

(F) hydroxypropyl cellulose (e.g. Klucel HF)	2.00
(G) Polysorbate 20 (e.g. Tween 20)	2.00
(H) ethanol 96% (v/v)	35.00
(I) water, demineralized	ad 100.0

- (i) Dissolve A in a mixture of E and H.
- (ii) Dissolve B, C, D and G in I.
- (iii) Mix (i) and (ii) at room temperature and add F.

Example 2: An emulsion-gel comprising 1% terbinafine free base and 0.5% diclofenac sodium is manufactured as follows.

<u>Ingredients</u>	<u>Amount (g/100g)</u>
(A) terbinafine free base	1.00
(B) diclofenac sodium	0.50
(C) Butyl hydroxy toluene	0.02
(D) sodium hydroxide (pellets)	0.10
(E) benzyl alcohol	0.50
(F) Carbopol 974 P (carbomer) [= acrylic acid polymerisate]	1.00
(G) sorbitan monolaurate (e.g. Span 20)	1.00
(H) Polysorbate 20 (e.g. Tween 20)	5.00
(I) ethanol 96% (v/v)	10.00
(J) isopropyl myristate	10.00
(K) water, demineralized	ad 100.0

- (i) A, J, C, E, G and H are mixed together with slight warming until all solid particles are dissolved.
- (ii) In an appropriate vessel or processor containing a stirrer and a homogenizer about half of K is heated to 60-70°C, and B is dissolved therein.
- (iii) (i) is slowly added to (ii) while stirring and homogenizing until a homogeneous emulsion with appropriate droplet size is obtained. The concentrated emulsion is then cooled to room temperature.
- (iv) In a separate vessel a basic carbomer gel is prepared by dispersing carbomer F in I and the second half of K and neutralizing with D.

(v) The basic emulsion (iii) is added to the basic gel and the whole is stirred at room temperature until a homogeneous emulsion gel is obtained.

Example 3: An emulsion-gel comprising 1% terbinafine free base and 0.25% diclofenac sodium is manufactured as follows.

<u>Ingredients</u>	<u>Amount (g/100g)</u>
(A) terbinafine free base	1.0
(B) diclofenac sodium	0.25
(C) isopropanol	20.0
(D) polyethylene glycol 300	3.0
(E) polyhydroxyethylene cetyl stearyl ether (e.g. Cetomacrogol 1000)	2.0
(F) paraffin oil, viscous	2.5
(G) coco-caprylate/caprate (e.g. Cetiol LC)	2.5
(H) Carbopol 974 P	1.0
(I) diethylamine	0.7
(J) sodium sulphite	0.1
(K) water, demineralized	ad 100.0

(i) H is dispersed in a portion of K by means of a rotor-stator homogeniser.

(ii) A solution of B, I, J and D in C as well as the remaining K is added thereto and distributed homogeneously.

(iii) To form the fatty phase, E, G and F are melted together at 75°. A is added to the fatty phase, and then the whole fatty phase is slowly added to the previously formed gel (ii) and emulsified.

Example 4: An emulsion-gel comprising 1% clotrimazole and 0.5% diclofenac sodium is manufactured as follows.

<u>Ingredients</u>	<u>Amount (g/100g)</u>
(A) clotrimazole	1.0
(B) diclofenac sodium	0.5
(C) isopropyl myristate	10.0
(D) Polysorbate 20	5.0

- 12 -

(E) sorbitan monolaurate	1.0
(F) benzyl alcohol	0.5
(G) Carbopol 974 P	1.0
(H) sodium hydroxide	0.1
(I) ethanol 96% (v/v)	10.0
(J) water, demineralized	ad 100.0

The emulsion-gel is manufactured in a manner analogous to Example 2.

Example 5: An emulsion-gel comprising 1% terbinafine free base and 0.1% diclofenac sodium is manufactured as follows.

<u>Ingredients</u>	<u>Amount (g/100g)</u>
(A) terbinafine free base	1.0
(B) diclofenac sodium	0.1
(C) isopropanol	20.0
(D) propylene glycol	5.0
(E) Cetomacrogol 1000 (polyhydroxyethylene cetyl stearyl ether)	2.0
(F) paraffin oil, viscous	2.5
(G) Cetiol LC (coco-caprylate/caprate)	2.5
(H) Carbopol 980 (carbomer)	1.4
(I) ammonia (conc. aqueous solution)	1.4
(J) sodium sulphite	0.1
(K) water, demineralized	ad 100.0

The emulsion-gel is manufactured in a manner analogous to Example 3.

Example 6: An emulsion-gel comprising 1% terbinafine free base and 0.5% indomethacin sodium is manufactured as follows.

<u>Ingredients</u>	<u>Amount (g/100g)</u>
(A) terbinafine free base	1.0
(B) indomethacin sodium	0.5
(C) isopropyl myristate	10.0

- 13 -

(D) Polysorbate 20	5.0
(E) sorbitan monolaurate	1.0
(F) benzyl alcohol	0.5
(G) Carbopol 974	1.0
(H) sodium hydroxide	0.1
(I) ethanol	10.0
(J) water, demineralized	ad 100.0

The emulsion-gel is manufactured in a manner analogous to Example 2.

Example 7: An emulsion-gel comprising 1% terbinafine free base and 0.5% indomethacin sodium is manufactured as follows.

<u>Ingredients</u>	<u>Amount (g/100g)</u>
(A) terbinafine free base	1.0
(B) Indomethacin sodium	0.5
(C) isopropanol	10.0
(D) propylene glycol	5.0
(E) Cetomacrogol 1000	2.0
(F) paraffin, liquid	2.5
(G) Cetiol LC	2.5
(H) Carbopol 974 P	1.4
(I) ammonia (conc. aqueous solution)	1.4
(K) water, demineralized	ad 100.0

The emulsion-gel is manufactured in a manner analogous to Example 3.

Claims

1. A pharmaceutical composition adapted to topical administration comprising an antifungal selected from the group consisting of terbinafine, naftifine, butenafine, bifonazole, clotrimazole, econazole, isoconazole, ketoconazole, miconazole, oxiconazole, sertaconazole, sulconazole, tioconazole, tolnaftate, terconazole, amorolfine, ciclopirox, undecylenic acid, and topically acceptable salts of any of said compounds, and a second drug selected from the group consisting of diclofenac, indomethacin, flufenamic acid, niflumic acid, flurbiprofen, ibuprofen, sulfasalazine, piroxicam, and topically acceptable salts of any of said compounds, together with at least one topically acceptable carrier.
2. A composition according to claim 1, wherein the antifungal is selected from the group consisting of terbinafine, naftifine, butenafine, bifonazole, clotrimazole, isoconazole, ketoconazole, miconazole, oxiconazole, sertaconazole, sulconazole, tioconazole, tolnaftate, terconazole, amorolfine, ciclopirox, undecylenic acid, and topically acceptable salts of any of said compounds, and the second drug is selected from the group consisting of diclofenac, Indomethacin, flufenamic acid, niflumic acid, flurbiprofen, sulfasalazine, piroxicam, and topically acceptable salts of any of said compounds.
3. A composition according to claim 1 or claim 2, wherein the antifungal is selected from the group consisting of terbinafine, naftifine, butenafine, bifonazole, clotrimazole, sertaconazole, sulconazole, tioconazole, amorolfine, ciclopirox, and topically acceptable salts of any of said compounds.
4. A composition according to any one of claims 1-3, wherein the second drug is selected from the group consisting of diclofenac, indomethacin, flufenamic acid, niflumic acid, piroxicam, and topically acceptable salts of any of said compounds.
5. A composition according to claim 1, wherein the antifungal is selected from the group consisting of terbinafine and topically acceptable salts thereof, and the second drug is selected from the group consisting of diclofenac, indomethacin, and topically acceptable salts of any of said compounds.

6. A composition according to claim 1, wherein the antifungal is terbinafine, or a topically acceptable salt thereof, and the second drug is diclofenac, or a topically acceptable salt thereof.

7. A composition according to any one of claims 1-6, which comprises, as antifungal, terbinafine or terbinafine hydrochloride.

8. A composition according to any one of claims 1-7, which comprises, as second drug, diclofenac, diclofenac sodium, diclofenac potassium, diclofenac diethylammonium or diclofenac epolamine.

9. A composition according to any one of claims 1-8, wherein the antifungal is present in a weight percentage of from 0.1% up to 10% and the second drug is present in a weight percentage of from 0.05% up to 10% of the total composition.

10. A composition according to any one of claims 1 to 9, which is in the form of an emulsion-gel, a gel, a foam gel, a cream, a lotion or a solution, a shampoo or a nail lacquer.

11. A pharmaceutical composition adapted to topical administration according to any one of claims 1-10 in the form of an emulsion comprising an oily phase comprising an antifungal as defined in any one of claims 1-10, and an aqueous phase comprising water, one or more solvents selected from the group consisting of C₁-C₄-alkanols, poly-hydroxy-C₂-C₅-alkanes and poly-C₂-C₅-alkylene glycols, a water-soluble or water-miscible nonionic surfactant, wherein no anionic surfactant is present, and a second drug as defined in any one of claims 1-10.

12. A composition according to claim 11, wherein the oily phase comprises terbinafine or a topically acceptable salt thereof, and the aqueous phase comprises water, a C₁-C₄-alkanol, a water-soluble or water-miscible nonionic surfactant, wherein no anionic surfactant is present, and a second drug selected from the group consisting of diclofenac, indomethacin and topically acceptable salts of any of said compounds.

13. A composition according to claim 12, wherein the second drug is diclofenac, or a topically acceptable salt thereof.

14. A composition according to any one of claims 11-13, wherein the oil forming the oily phase is isopropyl myristate or a mixture of coco-caprylate/caprate and liquid paraffin.
15. A composition according to any one of claims 11-14, wherein the weight ratio of the antifungal and the oil forming the oily phase is of from 1:3 up to 1:40.
16. A composition according to any one of claims 11-14, wherein the weight ratio of the antifungal and the second drug is of from 1:0.05 up to 1:5.
17. Use of an antifungal selected from the group consisting of terbinafine, naftifine, butenafine, bifonazole, clotrimazole, econazole, isoconazole, ketoconazole, miconazole, oxiconazole, sertaconazole, sulconazole, tioconazole, tolnaftate, terconazole, amorolfine, ciclopirox, undecylenic acid, and topically acceptable salts of any of said compounds, and a second drug selected from the group consisting of diclofenac, indomethacin, flufenamic acid, niflumic acid, flurbiprofen, ibuprofen, sulfasalazine, piroxicam, and topically acceptable salts of any of said compounds, (for the manufacture of a pharmaceutical composition adapted to topical administration) for the prevention or treatment of fungal infections.
18. Use according to claim 17, where the pharmaceutical composition manufactured is useful in fighting dermatophytes.
19. Use according to claim 17 or 18, wherein the antifungal is terbinafine or a topically acceptable salt thereof, and the second drug is selected from the group consisting of diclofenac, indomethacin, and topically acceptable salts of any of said compounds.